Genmab A (GMAB) Profit After Tax (2018 - 2026)

Genmab A (GMAB) has reported Profit After Tax for 9 consecutive years, with $303.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax fell 42.94% year-over-year to $303.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.8 billion (up 6.87% YoY), and the FY2025 full-year result was $963.0 million, down 15.0% from the prior year.
• Profit After Tax improved to $303.0 million in Q2 2026 per GMAB's latest filing, from $53.0 million in the prior quarter.
• Across five years, Profit After Tax topped out at $2.1 billion in Q3 2023 and bottomed at -$3.1 billion in Q4 2023.
• Historically, Profit After Tax has averaged $216.6 million across 5 years, with a median of $266.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Profit After Tax surged 211.09% in 2024, then plunged 72.82% in 2026.
• Over 5 years, Profit After Tax stood at $192.8 million in 2022, then sank by 1698.23% to -$3.1 billion in 2023, then jumped by 118.86% to $581.0 million in 2024, then surged by 60.41% to $932.0 million in 2025, then slumped by 67.49% to $303.0 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $303.0 million, $53.0 million, and $932.0 million for Q2 2026, Q1 2026, and Q3 2025 respectively.